J&J wins talc-related cancer case in California (JNJ:NYSE)
· seekingalpha.com
Johnson & Johnson (JNJ) stock is in focus as an LA jury finds that the firm is not negligent over ovarian cancer claims related to its talc products. Read more here.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...